Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about IMMUNE PHARMACEUTICALS, INC.
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
2019First Motion for Exclusivity Period Extension Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals Announces Leadership Transition
CI
2019Motion for Joint Administration Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Joint Administration Filed by Immune Pharmaceuticals, Inc.
CI
2019Affiliate Companies Joined Immune Pharmaceuticals, Inc. Bankruptcy
CI
2019Affiliate Company Joined Immune Pharmaceuticals, Inc. Bankruptcy
CI
2019Immune Pharmaceuticals, Inc. Filed for Bankruptcy
CI
2018Immune Pharmaceuticals and Vector Therapeutics Signs Option Agreement for Worldwide Cep..
CI
2018Immune Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended Septe..
CI
2018Immune Pharmaceuticals, Inc. Releases Additional Results from its Positive, Proof-of-Co..
CI
2018Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma
CI
2018Immune Pharmaceuticals, Inc. announced that it expects to receive $2 million in funding
CI
2018Immune Pharmaceuticals, Inc. announced that it has received $0.103 million in funding f..
CI
2018Immune Pharmaceuticals, Inc. announced that it expects to receive $0.103 million in fun..
CI
2018U.S. Food and Drug Administration Grants Fast Track Designation to Immune Pharmaceutica..
CI
2018Dr. Cameron Durrant Resigns from Immune Pharmaceuticals, Inc. as Director
CI
2018Immune Pharmaceuticals Inc. Announces Management Changes
CI
2018IMMUNE PHARMACEUTICALS, INC.(NASDAQC : IMNP) dropped from S&P TMI Index
CI
2018IMMUNE PHARMACEUTICALS, INC.(NASDAQC : IMNP) dropped from NASDAQ Composite Index
CI
2018Immune Pharmaceuticals Explores Strategic Options For Its Oncology And Other Non-Core A..
CI
2018Immune Pharmaceuticals Provides A Pipeline Update
CI
2018Immune Pharmaceuticals, Inc. Presents Updated Positive Results from Phase 2 Trial of Be..
CI
2018Immune Pharmaceuticals Inc. announced that it expects to receive $2.225 million in fund..
CI
2018Immune Pharmaceuticals In Talks To Sell Cytovia Assets
CI
2018Immune Pharmaceuticals Inc. Announces Resignation of Dr. Daniel Teper as Director
CI
2018Immune Pharmaceuticals Inc. cancelled the Spin-Off of Cytovia Oncology Inc.
CI
2018Immune Pharmaceuticals Seeks Sale of Cytovia Oncology
CI
2018Immune Pharmaceuticals Inc. Reports Consolidated Earnings Results for the Year Ended De..
CI
2018Certain July 2017 Notes of Immune Pharmaceuticals, Inc. are subject to a Lock-Up Agreem..
CI
2018Certain August 2017 Convertible Debentures of Immune Pharmaceuticals, Inc. are subject ..
CI
2018Certain May 2017 Notes of Immune Pharmaceuticals, Inc. are subject to a Lock-Up Agreeme..
CI
2018Certain April 2017 Notes of Immune Pharmaceuticals, Inc. are subject to a Lock-Up Agree..
CI
2018Certain Stock Options of Immune Pharmaceuticals, Inc. are subject to a Lock-Up Agreemen..
CI
2018Certain Warrants of Immune Pharmaceuticals, Inc. are subject to a Lock-Up Agreement End..
CI
2018Certain Common Stock of Immune Pharmaceuticals, Inc. are subject to a Lock-Up Agreement..
CI
2017Immune Pharmaceuticals Inc. Announces Management Changes
CI
2017Immune Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 2 Trial of B..
CI
2017Immune Pharmaceuticals, Inc. announced that it has received $0.66 million in funding
CI
2017Immune Pharmaceuticals Provides R&D and Business Update
CI
2017Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial..
CI
2017Immune Pharmaceuticals, Inc. announced that it expects to receive $0.66 million in fund..
CI
2017Immune Pharmaceuticals Appoints Tony Fiorino as Chief Medical Officer and Chief Operati..
CI
2017Immune Pharmaceuticals, Inc. announced the spin-off of Cytovia Oncology Inc.
CI
2017Cytovia Mulls Acquisitions
CI
2017Immune Pharmaceuticals, Inc. announced that it expects to receive $0.3 million in fundi..
CI
2017Immune Pharmaceuticals, Inc. Announces Initiation of Enrollment in Clinical Trial with ..
CI
2017Immune Pharmaceuticals Inc. Announces Resignation of Dr. Monica Luchi as Chief Medical ..
CI
2017Immune Pharmaceuticals, Inc. announced that it has received $1.5 million in funding
CI
2017Immune Pharmaceuticals, Inc. announced that it expects to receive $3.4 million in fundi..
CI
2017Immune Pharmaceuticals Inc. Announces Executive Changes
CI
2017Immune Pharmaceuticals, Inc. announced that it has received $0.45 million in funding fr..
CI
2017Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in Open L..
CI
2017Immune Pharma to Launch Combination Study for Acute Myeloid Leukemia Remission Maintena..
CI
2017Immune Pharmaceuticals, Inc. Announces Resignation of Ranch Kimball from the Board of D..
CI
2017Immune Pharmaceuticals, Inc. Announces Board Changes
CI
2017Immune Pharmaceuticals Inc. Enters into Research Partnership to Develop Mono- and Bispe..
CI
2016Immune Pharmaceuticals, Inc. announced that it expects to receive $1.05 million in fund..
CI
2016Immune Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for Seco..
CI
2016Immune Pharmaceuticals Seeks Acquisition
CI
2016Immune Pharmaceuticals, Inc. announced that it has received $0.35 million in funding fr..
CI
2016Immune Pharmaceuticals, Inc. announced that it expects to receive $0.35 million in fund..
CI
2016Immune Pharma Unveils Positive Pre-Clinical Data on Azixa as Combination Cancer Treatme..
CI
2016Immune Pharmaceuticals Inc. and Hadasit Files Provisional Patent on the Oral Use of Ant..
CI
2016Immune Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the ..
CI